On Mounjaro and not losing weight? Here's what might be happening

The first few weeks: what the early numbers usually look like

Picture this: it's week six, you've been injecting every Friday, you step on the scales on a Monday morning and the number is almost identical to the day you started. That's a genuinely disorienting place to be, and it's the scenario our prescribers hear about most weeks.

The reason is mostly about dose. Mounjaro's licensed schedule begins at 2.5 mg, a starting point whose job is to let your digestive system settle, not to produce large-scale weight reduction straight away. The timeline most people experience on Mounjaro shows that meaningful weight loss tends to arrive once the dose begins to climb, typically from 5 mg upward, with the most substantial changes often seen at 10 mg and above.

The SURMOUNT-1 trial, which found average body-weight reductions of around 20–21% at 15 mg over 72 weeks, was measuring people across a full titration schedule, not the first six weeks at the starting dose. The published SURMOUNT-1 data in the New England Journal of Medicine makes this clear: the weight curves kept declining for months. That context matters if you're still early in treatment and frustrated by slow movement on the scales.

Short plateaus are also physiologically normal. The body sometimes pauses fat loss while it recalibrates energy balance, this can last two to four weeks even on an effective dose. If you're in that position, our page on what to consider when you're on Mounjaro and not losing weight can help you think through whether what you're experiencing is a temporary pause or something worth investigating further.

What could genuinely be slowing your progress on tirzepatide

Not losing weight on Mounjaro despite injecting regularly is worth unpacking rather than dismissing. Several things can reduce the medicine's effect.

Total energy intake is the most straightforward. Tirzepatide works partly by reducing appetite, but it doesn't make it impossible to eat past fullness, particularly with highly palatable, calorie-dense foods that the brain finds rewarding regardless of hunger signals. If your diet has shifted toward processed foods, or portions have crept up again after the initial appetite suppression, calories may still exceed what your body is burning.

Sleep and stress are less obvious but well-established. Poor sleep elevates cortisol and ghrelin, both of which drive appetite upward and can counteract GLP-1 effects. A stressful period (a work deadline, a difficult family situation) can produce exactly this pattern, and some people only recognise it retrospectively.

Other medicines are worth checking. Some antidepressants, antipsychotics, corticosteroids and beta-blockers are associated with weight gain or resistance to weight loss. If you started a new medication around the time your progress stalled, that's worth flagging. You can read more about the range of factors that affect results on our detailed page on why some people don't lose weight on Mounjaro.

Finally, and it sounds obvious but matters: injection technique. Mounjaro is a subcutaneous injection; if the pen isn't making consistent skin contact at the right depth, absorption can be inconsistent. Rotating sites between the abdomen, thigh and upper arm (and checking the pen has actually fired) helps rule this out.

When to take it seriously, and when to adjust expectations

There's a difference between a slow start and a genuine non-response. The NHS guidance, following NICE's appraisal of tirzepatide, is clear: if you have lost less than 5% of your starting body weight after six months at the highest dose you've tolerated, continuing treatment should be reviewed. NICE TA1026 sets out this threshold specifically, and it's a useful reference point for your own assessment.

If you're nowhere near six months in, the picture is much more open. But if you're at month four or five on a mid-to-high dose and the scales have barely moved, it's time to speak to your prescriber rather than wait it out in silence. Some people respond better to one GLP-1 mechanism than another, why tirzepatide may not be producing results for you specifically is a question a prescriber can help to answer, taking your full medical history into account.

There's also the matter of muscle mass. If you've taken up resistance exercise since starting Mounjaro (genuinely a good idea, since GLP-1 medicines can cause some lean-mass loss alongside fat) the scale may not reflect fat reduction accurately. Waist measurements and how clothes fit can be more informative in the short term. If you're curious about what options exist beyond your current treatment, our weight-loss treatment overview covers the landscape.

What to do next if you're still not seeing results

The practical starting point is a clinical conversation. If you find yourself not losing any weight on Mounjaro after a reasonable period on a therapeutic dose, that is information your prescriber needs, and our dedicated page covers the specific questions worth raising with them. They can look at your current dose, review whether a titration is appropriate, check for any clinical reason weight loss might be blunted, and consider whether the treatment plan needs adjusting.

Stopping and restarting Mounjaro without clinical guidance is rarely the answer, abrupt changes to the schedule carry their own considerations, and our guidance on stopping and restarting Mounjaro explains why that decision should involve your prescriber. Similarly, adjusting your dose unilaterally (speeding up titration in the hope of faster results) can increase side-effect risk without proportionate benefit.

For lifestyle factors, the evidence consistently points to protein intake, hydration and sleep as the levers most worth pulling alongside the medicine. Aiming for adequate protein at each meal helps preserve muscle and may support the appetite effects of tirzepatide. It's also worth reviewing whether your calorie target still reflects your current body weight, as you lose weight, energy needs fall, and what was a deficit six months ago may now be roughly maintenance.

The NHS's tirzepatide medicines page covers practical guidance on how the treatment works and what to expect; it's a reliable place to cross-check what you're experiencing. If you have ongoing concerns, or you're looking for a prescriber who can review your situation properly, the free consultation at nume connects you with a GPhC-registered prescriber (a real clinician reads your answers, not an automated system) and aftercare is available seven days a week so you're not left navigating this alone.